-+ 0.00%
-+ 0.00%
-+ 0.00%

Borui Pharmaceutical (688166.SH) subsidiary obtained tiotropium bromide inhalation spray drug registration certificate

Zhitongcaijing·07/31/2026 07:57:02
Listen to the news

Zhitong Finance App News, Borui Pharmaceutical (688166.SH) issued an announcement. Recently, Atmy (Suzhou) Pharmaceutical Technology Co., Ltd., a holding subsidiary of the company, received the “tiotropium bromide inhalation spray” and “Drug Registration Certificate” issued by the State Drug Administration. Tiotropium bromide inhalation spray is suitable for the maintenance and treatment of chronic obstructive pulmonary disease (COPD, COPD, including chronic bronchitis and emphysema) and related breathing difficulties, improving the quality of life of COPD patients and reducing acute exacerbation of COPD.

The original manufacturer of tiotropium bromide inhalation spray is Boehringer Ingelheim. Currently, there are only imported varieties of drugs in the market. According to the official website of the State Drug Administration, there are currently no generic drugs for this drug on the market in China. The company is the first domestic company to be approved for marketing generic drugs.

According to statistics, global sales of tiotropium bromide inhalation spray in 2023 were US$1,842 billion, global sales in 2024 were US$1,770 billion, and global sales in 2025 were US$1.67 billion. (Data from IQVIA database)